---
title: "Apogee Therapeutics, Inc. (APGE.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/APGE.US.md"
symbol: "APGE.US"
name: "Apogee Therapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-05-21T12:21:21.851Z"
locales:
  - [en](https://longbridge.com/en/quote/APGE.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/APGE.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/APGE.US.md)
---

# Apogee Therapeutics, Inc. (APGE.US)

## Company Overview

Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.apogeetherapeutics.com](https://www.apogeetherapeutics.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -22.30 | 505 | - | - | - |
| PB | 4.88 | 318 | 8.08 | 5.74 | 3.52 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-18T04:00:00.000Z

Total Analysts: **19**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 15 | 79% |
| Hold | 3 | 16% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 81.39 |
| Highest Target | 160.00 |
| Lowest Target | 82.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/APGE.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/APGE.US/norm.md)
- [Related News](https://longbridge.com/en/quote/APGE.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/APGE.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**